An improved delivery particle comprising a benefit agent core material and a shell encapsulating the core material is described, along with a process for forming such a delivery particle and articles of manufacture. The shell is the reaction product of: i) an isocyanate or acid chloride or acrylate with ii) an amine-containing natural material having free amino moieties, and iii) an a, β -unsaturated compound, the a, β -unsaturated compound forming C-N covalent bonds with the amine moieties of the natural material. The delivery particle of the invention has improved release characteristics, with enhanced degradation characteristics in OECD test method 301B.

The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition.

An encapsulated bacteriophage formulation and a method for encapsulating bacteriophages and bacteriophage-related products in polymeric microcapsules is provided. Some embodiments of the method of producing the encapsulated bacteriophages involves a water-in-oil-in-water double emulsion.

The present disclosure generally relates to a composition matter and a method for cancer treatment comprising albumin (alb) coated tannic acid-Fe nanoparticles (NPs) with a therapeutic compound, and one or more diluents, excipients or carriers. In particular, the present invention provides a treatment by enhancing antitumor immunity using tannic acid-based nanoparticles containing a therapeutic cancer treatment that can induce immunogenic cell death (ICD). The method disclosed herein provides a potential solution to the immunotoxicity accompanying the ICD cancer immunotherapy by intratumoral or intravenous administration of a nanocapsule formulation of carfilzomib (CFZ), an ICD-inducing proteasome inhibitor, using interfacial supramolecular assembly of tannic acid (TA) and iron, supplemented with albumin coating for better metabolic stability.

Peptide-encapsulating ferritins including a peptide that is composed of 3 to 19 amino acid residues and satisfies the following requirement:

a) −10.2≤X≤5.9 and 445≤Y≤2,524

wherein X represents a charge of the peptide at pH 9, and I represents a chemical formula weight of the peptide are useful for transporting a peptide while avoiding destruction of cellular membrane, immunogenicity, and toxicity

A microcapsule and a preparation method thereof, especially a multi-layer microcapsule containing an active substance and a preparation method thereof, the microcapsule having a single-layer or a multiple-layer encapsulation structure. A probiotic microcapsule and a preparation method thereof, the probiotic microcapsule having a single-layer or a multi-layer encapsulation structure. A food product or a health product containing a probiotic microcapsule (comprising a dairy product, a fermented-style food product, a beverage, chocolate, candy, a baked good, a fruit or vegetable juice product, etc. containing a probiotic microcapsule) and a preparation method thereof. A probiotic microcapsule soft powder and a preparation method thereof, the probiotic microcapsule soft powder comprising probiotic microcapsule nata de coco soft powder and probiotic microcapsule gel ball soft powder.

Coated and Dried extracellular vesicles (EVs) represent an ideal method for preservation and increasing the shelf life-time of the invention making it ready to use on time and on variety of species overcoming the previous challenges on isolation and preservation and undesirable immune responses. The invention compromises a coated freeze dried stem cells derived EVs that are ready for use to Stimulate/accelerate healing of soft/hard tissues, can be reconstituted in multiple forms and shapes and stimulated by Laser. The nature of the invention is a heterogenous and/or Xenogenous EVs which can overcome the challenges of individual and/or species diseases and immune reactions.

This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

An article of manufacture is described comprising the combination of an adjunct material and a delivery particle. The delivery particle comprising a benefit agent core material and a shell encapsulating the core material is described, along with a process for forming such a delivery particle and articles of manufacture. The shell is the reaction product of: i) an isocyanate or acid chloride or acrylate with ii) an amine-containing natural material having free amino moieties, and iii) an α, β-unsaturated compound, the α, β-unsaturated compound forming C—N covalent bonds with the amine moieties of the natural material. The delivery particle of the invention has improved release characteristics, with enhanced degradation characteristics in OECD test method 301B.

This disclosure provides nicotine-loaded microcapsules for use in treating or preventing nicotine dependence, or a withdrawal symptom thereof, in a subject in need thereof. The disclosure also provides pharmaceutical compositions and pharmaceutical formulations comprising nicotine-loaded microcapsules. The disclosure also provides methods of making nicotine-loaded microcapsules.